Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDBioline Rx Ltd Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 1 | -$1.04 | -$1.04 | -$1.04 |
| Q2 2026 | 1 | -$0.32 | -$0.32 | -$0.32 |
| Q3 2026 | 1 | -$0.19 | -$0.19 | -$0.19 |
| Q4 2026 | 1 | -$0.19 | -$0.19 | -$0.19 |
Bioline Rx Ltd Earnings Date And Information
Bioline Rx Ltd last posted its earnings results on Monday, March 23rd, 2026. The company reported $-0.34 earnings per share for the quarter, topping analysts' consensus estimates of $-0.5 by $0.16. The company had revenue of 195.21 K for the quarter and had revenue of 1.19 M for the year. Bioline Rx Ltd has generated $0 earnings per share over the last year ($-0.29 diluted earnings per share) and currently has a price-to-earnings ratio of -11.21. Bioline Rx Ltd has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Bioline Rx Ltd Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 03/23/2026 | Q4 2025 | -$0.50 | -$0.32 | 0.18 | $514.00 K | $195.21 K |
| 03/23/2026 | Q3 2025 | -$0.50 | -$0.22 | 0.28 | N/A | $427.00 K |
| 08/14/2025 | Q2 2025 | -$0.35 | -$1.00 | -0.65 | $661.33 K | $304.00 K |
| 03/31/2025 | Q1 2025 | N/A | $0.06 | N/A | $1.48 M | $255.00 K |
| 03/31/2025 | Q4 2024 | N/A | -$0.04 | N/A | $7.72 M | $11.75 M |
| 09/30/2024 | Q3 2024 | N/A | -$0.07 | N/A | $5.29 M | $4.94 M |
| 06/29/2024 | Q2 2024 | N/A | $0.01 | N/A | $3.93 M | $5.39 M |
| 03/30/2024 | Q1 2024 | N/A | -$0.01 | N/A | $340.00 K | $6.86 M |
| 03/26/2024 | Q4 2023 | -$0.22 | -$0.19 | 0.03 | N/A | $4.80 M |
| 09/29/2023 | Q3 2023 | N/A | -$0.26 | N/A | N/A | $0 |
| 06/29/2023 | Q2 2023 | N/A | -$0.30 | N/A | N/A | $0 |
| 03/30/2023 | Q1 2023 | N/A | -$0.19 | N/A | N/A | $0 |
| 03/22/2023 | Q4 2022 | -$5.60 | -$0.06 | 5.54 | N/A | $0 |
| 09/29/2022 | Q3 2022 | N/A | -$0.13 | N/A | N/A | $0 |
| 08/16/2022 | Q2 2022 | -$5.60 | -$0.15 | 5.45 | N/A | $0 |
| 05/11/2022 | Q1 2022 | -$6.00 | -$0.08 | 5.92 | N/A | $0 |
| 03/16/2022 | Q4 2021 | -$5.60 | -$0.10 | 5.5 | N/A | $0 |
| 11/18/2021 | Q3 2021 | -$5.20 | -$0.12 | 5.08 | N/A | $0 |
| 08/18/2021 | Q2 2021 | -$4.80 | -$0.15 | 4.65 | N/A | $0 |
| 05/26/2021 | Q1 2021 | -$6.00 | -$0.27 | 5.73 | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Bioline Rx Ltd Earnings: FAQ's
In the previous quarter, Bioline Rx Ltd (:BLRX) reported $-0.34 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.5 by $0.16.
The conference call for Bioline Rx Ltd's latest earnings report can be listened to online.
The conference call transcript for Bioline Rx Ltd's latest earnings report can be read online.
Bioline Rx Ltd (:BLRX) has a recorded annual revenue of $1.19 M.
Bioline Rx Ltd (:BLRX) has a recorded net income of $-1,184,321.Bioline Rx Ltd has generated $-0.29 earnings per share over the last four quarters.
Bioline Rx Ltd (:BLRX) has a price-to-earnings ratio of -11.21 and price/earnings-to-growth ratio is -0.07.